SynthesisFrontiers in oncology2020
Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Synthesis in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.Frontiers in oncology · 2022Pooled it
- Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Evidence of the Prognostic Value of Pretreatment Systemic Inflammation Response Index in Cancer Patients: A Pooled Analysis of 19 Cohort Studies.Disease markers · 2020Pooled it
- Recurrent Distant Metastatic Endometrial Cancer Treated with Immunotherapy with Pembrolizumab: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Immunoexpressions of PD-L1 and EZH2 in Endometrial Carcinoma: Associations with Clinicopathological Parameters.Diagnostics (Basel, Switzerland) · 2025Article
- PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature.Journal of clinical medicine · 2025Review
- Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- BUB1, BUB1B, CCNA2, and CDCA8, along with miR-524-5p, as clinically relevant biomarkers for the diagnosis and treatment of endometrial carcinoma.BMC cancer · 2023Article
- Article
- Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer.International journal of molecular sciences · 2023Article
- Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.OncoTargets and therapy · 2023Review
- Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).Cancers · 2022Article
- STK4 protein expression pattern follows different trends in endometrioid and serous endometrial adenocarcinoma upon tumor progression.Scientific reports · 2022Article
- Review
- Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?International journal of molecular sciences · 2022Review
- Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group.Frontiers in oncology · 2022Review
- Differential Characteristics and Prognosis of PD-L1-Positive Endometrial Carcinomas: A Retrospective Chart Review.Life (Basel, Switzerland) · 2021Article
- Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.Biomedicines · 2021Review
- Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.Cancer communications (London, England) · 2021Article
- PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.